EUROGREEN-MARITIME-SAS
8.4.2024 13:31:29 CEST | Business Wire | Press release
EuroGreen Maritime SAS (EGM), a pioneering French shipping company at the forefront of sustainable maritime solutions, announced today that it has solidified its commitment to environmental excellence by entering into a seven-year charter agreement for four vessels with the Norwegian energy company Equinor ASA (NYSE: EQNR) after being awarded the contract of the tender process initiated in December 2023. This transaction represents a significant advancement in green shipping and underscores a shared vision for a cleaner, more sustainable maritime industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408231181/en/
(Photo: Business Wire)
Innovative marine technology for a greener future
Under this landmark agreement, EGM will deliver four state-of-the-art MR IMO II Product Tankers developed in collaboration with LMG Marin France to set new standards in eco-friendly shipping, which rely on proven, commercial-utilized technologies. The vessels, scheduled for delivery starting in the first half of 2026 through 2027 and representing a value of more than US$250 million at delivery, will be built at Wuhu Shipyard Co., Ltd.'s new facility in Weihai, China. These ships will be managed on behalf of EGM by V.Ships France under this time charter agreement with Equinor upon delivery.
Each tanker features scaled, cutting-edge technology, including a MAN B&W dual-fuel methanol engine with a shaft generator complemented by a battery-hybrid power generation system, ensuring efficient and environmentally friendly operation and cold ironing shore power. In addition, the vessels are further equipped with wind assistance propulsion based on a pair of OceanWings® wingsails systems developed by the French company AYRO, enhancing their green credentials. GHG, SOx, and NOx emissions are reduced by more than 45%, 95%, and 50%, respectively, with no particles compared to conventional MR designs exceeding IMO 2030 targets.
Specifications and operations
- Vessel type: MR IMO II chemical tankers, 18 tanks, 12 segregations, MarineLINE® coating for optimal cargo operation.
- Eco propulsion: Powered by a dual-fuel methanol engine with a shaft generator.
- Wind assistance system: An innovative pair of OceanWings® by AYRO significantly reduces fuel consumption and emissions.
- Battery pack: Incorporating a large battery pack to improve power management.
- Shore power connection: To cut emissions during port operations.
- Flag and management: The four tankers will proudly fly the French flag and be managed by the esteemed ship manager, V.Ships France, of Nantes.
A strategic move for sustainable shipping
Equinor ASA plans to deploy these technologically advanced vessels into product trading activities. This initiative represents a significant step in reducing maritime operations' environmental footprint, further aligning with EGM's and Equinor's sustainability goals.
About EuroGreen Maritime (EGM)
EuroGreen Maritime is a visionary shipping company based in France, dedicated to leading the transition towards more sustainable maritime practices. Through innovation and collaboration, EGM is committed to reducing the environmental impact of shipping and promoting cleaner seas for future generations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408231181/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom